Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial intelligence – attracted a significant four-million-euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.
In a significant milestone, Azalea Vision, pioneering start-up on a mission to revolutionize the treatment of ocular disorders, announces the successful demonstration of ALMA Lens, the first functional prototype of the Azalea smart contact lens’ platform.
ATHENA, a VLAIO-funded multi-stakeholder project, clears the path for increased reuse of Real-World Data in scientific research and healthcare, by introducing innovative solutions and responding to current technical and governance challenges. The project has made significant strides in the field of oncology by developing groundbreaking privacy-preserving machine learning techniques for predictive analytics. The project findings will be presented and discussed at the ATHENA symposium on November 23rd, 2023.
The ´Science for health´ congress gathers local and global experts in Brussels on November 28 to discuss how to adapt healthcare to current challenges, combining cutting-edge technology with biology and place Belgium at the forefront of healthcare innovation.
Even though endometriosis impacts millions of women globally, the condition remains poorly understood and researched, leading to delayed diagnosis and lack of effective treatment. Encouragingly, there are promising recent developments in the field coming from Belgium. Professor Hugo Vankelecom’s research group at KU Leuven uses advanced cellular models, known as organoids, to delve into the disease and expedite the drug discovery process. The Danish BioInnovation Institute now offers the team an incubation program to pave the way towards industrial success.
It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a rush of ‘pink’ fundraising for women’s health start-ups. From pre-clinical to clinical: more companies are entering the field and developing solutions for women’s unique needs. But is their focus broad and innovative enough? And are pharma companies paying attention?
After a therapeutic drug hits the market, it is crucial to continuously gather, analyze, and report data regarding its safety and potential side effects, a practice known as pharmacovigilance. Unlike clinical trials, this involves real-world data (RWD), presenting unique challenges in terms of both quality and quantity. The Belgian BELpREG project seeks to employ RWD for monitoring drug utilization during pregnancy and investigating potential safety implications for both maternal and child health. This initiative holds great promise, although it faces substantial hurdles on its path to success.
Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience in diseases like Alzheimer’s and Parkinson’s, providing much-needed hope for millions of patients and their loved ones.
Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.
Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial intelligence – attracted a significant four-million-euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.
In a significant milestone, Azalea Vision, pioneering start-up on a mission to revolutionize the treatment of ocular disorders, announces the successful demonstration of ALMA Lens, the first functional prototype of the Azalea smart contact lens’ platform.
ATHENA, a VLAIO-funded multi-stakeholder project, clears the path for increased reuse of Real-World Data in scientific research and healthcare, by introducing innovative solutions and responding to current technical and governance challenges. The project has made significant strides in the field of oncology by developing groundbreaking privacy-preserving machine learning techniques for predictive analytics. The project findings will be presented and discussed at the ATHENA symposium on November 23rd, 2023.
The ´Science for health´ congress gathers local and global experts in Brussels on November 28 to discuss how to adapt healthcare to current challenges, combining cutting-edge technology with biology and place Belgium at the forefront of healthcare innovation.
Even though endometriosis impacts millions of women globally, the condition remains poorly understood and researched, leading to delayed diagnosis and lack of effective treatment. Encouragingly, there are promising recent developments in the field coming from Belgium. Professor Hugo Vankelecom’s research group at KU Leuven uses advanced cellular models, known as organoids, to delve into the disease and expedite the drug discovery process. The Danish BioInnovation Institute now offers the team an incubation program to pave the way towards industrial success.
It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a rush of ‘pink’ fundraising for women’s health start-ups. From pre-clinical to clinical: more companies are entering the field and developing solutions for women’s unique needs. But is their focus broad and innovative enough? And are pharma companies paying attention?
After a therapeutic drug hits the market, it is crucial to continuously gather, analyze, and report data regarding its safety and potential side effects, a practice known as pharmacovigilance. Unlike clinical trials, this involves real-world data (RWD), presenting unique challenges in terms of both quality and quantity. The Belgian BELpREG project seeks to employ RWD for monitoring drug utilization during pregnancy and investigating potential safety implications for both maternal and child health. This initiative holds great promise, although it faces substantial hurdles on its path to success.
Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience in diseases like Alzheimer’s and Parkinson’s, providing much-needed hope for millions of patients and their loved ones.
Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.